PubMed
Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline
Molitch ME, Clemmons DR, Malozowski S, et al. J Clin Endocrinol Metab. 2011
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 53% · Mixed 34% · Unfavorable overall 13%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.01–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 63% said they felt similar to their last entry, 39% more positive, and 13% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 19 days · Based on 20 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 45% · Mixed 38% · Unfavorable overall 17%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.01–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 55% said they felt similar to their last entry, 43% more positive, and 15% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 32 days · Based on 137 repeat reporters
Published sources linked on the HGH (Somatropin) and Tesamorelin wiki pages.
PubMed
Molitch ME, Clemmons DR, Malozowski S, et al. J Clin Endocrinol Metab. 2011
PubMed
Mameli C, Orso M, Calcaterra V, et al. Pharmacological research. 2023
PubMed
Colao A, Grasso LFS, Giustina A, et al. Nature reviews. Disease primers. 2019
FDA Drug Label
Theratechnologies. FDA Drug Label. 2010
PubMed
Ghigo E, Arvat E, Camanni F. Endocrine. 2008
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
FDA Drug Label
Theratechnologies. FDA Drug Label. 2019
PubMed
Spooner LM, Olin JL. The Annals of pharmacotherapy. 2012
PubMed
2018